OS Therapies (OSTX)
OS Therapies Statistics
Share Statistics
OS Therapies has 21.66M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 21.66M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 573 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is -, so null% of the outstanding shares have been sold short.
| Short Interest | - |
| Short % of Shares Out | null% |
| Short % of Float | null% |
| Short Ratio (days to cover) | null |
Valuation Ratios
The PE ratio is -0.06 and the forward PE ratio is null. OS Therapies's PEG ratio is 0.
| PE Ratio | -0.06 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | 0.7 |
| PB Ratio | 0.09 |
| P/FCF Ratio | -0.07 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for OS Therapies.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1195.84, with a Debt / Equity ratio of 0.
| Current Ratio | 1195.84 |
| Quick Ratio | 1195.84 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | 3.32 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.96B |
| Employee Count | 3 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is -5.96, so OS Therapies's price volatility has been lower than the market average.
| Beta | -5.96 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 1.68 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 31.66 |
| Average Volume (20 Days) | 1.19M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -6.81B |
| Net Income | -8.88B |
| EBITDA | -6.81B |
| EBIT | -10.93B |
| Earnings Per Share (EPS) | -71.77 |
Balance Sheet
The company has 5.53M in cash and 0 in debt, giving a net cash position of 5.53M.
| Cash & Cash Equivalents | 5.53M |
| Total Debt | 0 |
| Net Cash | 5.53M |
| Retained Earnings | -40.4B |
| Total Assets | 5.54M |
| Working Capital | 906.22K |
Cash Flow
In the last 12 months, operating cash flow was -7.28B and capital expenditures 0, giving a free cash flow of -7.28B.
| Operating Cash Flow | -7.28B |
| Capital Expenditures | 0 |
| Free Cash Flow | -7.28B |
| FCF Per Share | -58.84 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OSTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for OSTX is $19.5, which is 1525% higher than the current price. The consensus rating is "Buy".
| Price Target | $19.5 |
| Price Target Difference | 1525% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -10.51 |
| Piotroski F-Score | 2 |